BioSpace News Archive

MaaT Pharma (EURONEXT: MAAT – the “Company”) announced today that it has received regulatory authorizations for its two clinical trial applications evaluating MaaT033 in hemato-oncology and in amyotrophic lateral sclerosis (ALS).

Centene Corporation announced the appointment of Tanya McNally to Senior Vice President and Chief People Officer of Centene.

Macmillan Learning, a privately-held, family-owned education publishing and service company, is seeking instructors teaching Introduction to Psychology or Introduction to Biology this fall to participate in research on closing equity gaps through evidence-based teaching practices.

Vaporox, a Denver based medical device company, has received clearance from the US Food and Drug Administration for its next generation VHT-200 medical device system for healing chronic wounds, which are wounds that do not respond to conventional wound treatment, meeting a significant unmet medical need for millions of sufferers of diabetic foot ulcers.

Applied Molecular Transport Inc. announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.

NeuroSense Therapeutics Ltd. today announced it has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital’s NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).

Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.

BPGbio Inc announced today that the company has reached a partnership agreement with Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial, which is anticipated to launch in the second half of the year.

KromaTiD, a single-cell analysis life science tools company focused on the research, development, and commercialization of technology solutions for the cell and gene therapy market, today announced the launch of the dGH in-Site™ CAR-T Kit.